See All News >
Genentech (RHHBY)'s Ocrelizumab Wows in Late Stages and Eyes $18 Billion MS Market
Juno Therapeutics (JUNO) Stock Soars After Celgene (CELG) Acquires $1 Billion Stake in Seattle Company
Vertex (VRTX) Poised to Become Profitable Following Expected FDA Approval of Orkambi
New Sarepta (SRPT) CEO's Strategy Bears Fruit With NDA Filing
Amgen (AMGN) To Lay Off 330 in Colorado as Part of Almost 4,000 Jobs Cuts Overall
Roche (RHHBY) Investors Urging Company to Dump Diabetes Unit May Have to Wait
Two Yale University Health Info Groups Sue FDA, Gilead (GILD) for Hep C Drug Trial Data
EXCLUSIVE: Analysts Weigh In On Controversial Juno Therapeutics (JUNO)/Celgene (CELG) Deal, With Mixed Feelings Abounding
Hikma (HIK.L) Rumored to Be Bidding $2.2B for Boehringer Ingelheim's Roxane Laboratories, As Mallinckrodt (MNK), Perrigo (PRGO) Circle
Bristol-Myers Squibb (BMY) to Lay Off 100 in Discovery, Move 200 Workers to New Cambridge R&D Hub
AMAG (AMAG) Coughs Up $700 Million for Stem Cell Company
You Can Freeze Your Fat And Poop It Out
Merck & Co. (MRK) Slashes Contractor Positions at Durham Vaccine Manufacturing Plant
GlaxoSmithKline (GSK)'s Major Gene Discovery Paves Way for "Home Brew" Heroine
BioSpace (DHX) Temperature Poll: After Bristol-Myers Squibb (BMY) Wonder Drug Meets Endpoints, Will FDA Process Be Up to Snuff?
Billionaire Doctor's NantHealth Inches Closer to an IPO
EXCLUSIVE: Knives Are Out for Biotech, As Bears Snag Options for Bubble Burst
Vitae Pharma (VTAE)’ Diabetes Drug Fails Mid-Stage Trial, the Second Drug in Less Than Six Months to Fail
See All News >
//-->